Price
$1.41+14.63%Social Signal Score
Analyst Ratings
Revenue
No revenue history available for this company.
Analyst Estimates
Consensus estimates, not results. Via Financial Modeling Prep.
Company Profile
- CEO
- John Fowler
- Sector
- Healthcare
- Industry
- Biotechnology
- Employees
- 85
- Beta
- 0.80
- Country
- IL
Financials
Quote
Valuation & Ratios
Returns & Efficiency
Revenue & Net Income (Annual)
| Fiscal Year | Revenue | Net Income | EPS |
|---|---|---|---|
| 2025 | $0.00 | $4.14M | $4.62 |
| 2024 | $0.00 | $-25.15M | $-30.10 |
| 2023 | $0.00 | $-17.57M | $-21.00 |
| 2022 | $0.00 | $-19.11M | $-23.59 |
| 2021 | $0.00 | $-17.20M | $-21.21 |
Valuation
Project earnings forward and see what return today's price implies.
EPS was negative in at least one boundary year, so a compound growth rate can't be computed from it. Set your own assumption.
- EPS in 5 years
- $6.83
- Implied price
- $122.98
- Return from $3.29
- 106.3% a year
To earn 15.0% a year on these assumptions you'd need to buy at $61.14 — today's price is already 94.6% below that.
How sensitive is that answer?
Annual return across nearby assumptions. If the result is only attractive in one corner, that is the finding.
| growth \ P/E | 12 | 15 | 18 | 21 | 24 |
|---|---|---|---|---|---|
| -2.0% | 72.6% | 80.5% | 87.2% | 93.1% | 98.3% |
| 3.0% | 81.4% | 89.7% | 96.8% | 102.9% | 108.4% |
| 8.0% | 90.2% | 98.9% | 106.3% | 112.8% | 118.5% |
| 13.0% | 99.1% | 108.1% | 115.9% | 122.6% | 128.7% |
| 18.0% | 107.9% | 117.3% | 125.4% | 132.5% | 138.8% |
This is arithmetic on assumptions you chose, not a forecast or a recommendation. It ignores dividends, buybacks, share issuance and debt, and it assumes a company still earning money in 5 years. Change any input and the answer changes a lot — that sensitivity is the honest result, not a flaw in the model.
Signal Score (90d)
100+0.00%Social Signal Score
Mentions (6)
- Newsglobenewswire.com·20d ago·Neutral
MBody AI Completes Name Change Following Merger and $10 Million Offering Nasdaq-listed embodied AI company introduces its operating platform, enterprise deployments and updated market identifiers Nasdaq-listed embodied AI company introduces its operating platform, enterprise deployments and updated market identifiers
View source ↗ - Newsglobenewswire.com·27d ago·Neutral
MBody AI Advances AI Robotics Rollout at Mohegan Sun MBody AI Ltd. (NASDAQ: MBAI) completes successful Mohegan Sun pilot deployment and begins negotiation on planned commercial expansion MBody AI Ltd. (NASDAQ: MBAI) completes successful Mohegan Sun pilot deployment and begins negotiation on planned commercial expansion
View source ↗ - Newsglobenewswire.com·39d ago·Negative
…rger, Closes $10 Million Underwritten Offering ISFIYA, Israel and LAS VEGAS, Aug. 28, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: MBAI), an embodied artificial intelligence company, announced today the completion of its business combination with MBody AI Corp. on August 26, 2026 (the “Merger”) and the closing of its firm-commitment underwritten public offering (the “Offering”) of 1,538,462 ordinary shares at a public offering price of $6.50 per share, before u…
View source ↗ - Newsglobenewswire.com·41d ago·Negative
Check-Cap Ltd. Announces Pricing of $10 Million Public Offering of Ordinary Shares ISFIYA, Israel, Aug. 26, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (the “Company” or “Check-Cap”) (NASDAQ: MBAI), an embodied artificial intelligence company, announced today the pricing of its public offering of 1,538,462 Ordinary Shares at a public offering price of $6.50 per share, before underwriting discounts and commissions.
View source ↗ - Newsglobenewswire.com·54d ago·Neutral
Check-Cap (MBAI) Advances Merger with MBody AI; Reverse Share Split Effective Check-Cap Ltd. (NASDAQ: MBAI) advanced its proposed merger with physical AI company, MBody AI Corp., completing a planned 1-for-7 reverse share split Check-Cap Ltd. (NASDAQ: MBAI) advanced its proposed merger with physical AI company, MBody AI Corp., completing a planned 1-for-7 reverse share split
View source ↗ - Newsglobenewswire.com·59d ago·Neutral
Check-Cap Announces Reverse Share Split ISFIYA, Israel, Aug. 07, 2026 (GLOBE NEWSWIRE) -- Check-Cap Ltd. (“Check-Cap” or the “Company”) (NASDAQ: MBAI) today announced a 1-for-7 reverse share split (the “Reverse Share Split”) of the Company's ordinary shares.
View source ↗
Earnings
Wed, Mar 3(in 5 months)
Consensus estimate $-0.01 per share
Typical surprise +26.8% (median, so one quarter with a near-zero estimate can't distort it)
- Mon, Nov 27$-3.08 vs $-5.81beat
- Fri, Aug 4$-8.26 vs $-3.15miss
- Fri, Mar 31$-4.45 vs $-4.76beat
- Wed, Nov 30$-0.28 vs $-6.30beat
Estimates and results for MBAI via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.
Insider trading
Open-market buys and sells by MBAI officers and directors.
No open-market trades in the recent filings. All 13 recent Form 4 entries were share awards, option exercises or tax withholding — pay, not decisions to buy or sell.
13 further Form 4 entries are share awards, option exercises or shares withheld for tax. Those are compensation, not trades, so they are excluded above. Buying is the stronger signal: an insider spends their own money for one reason. Selling has many innocent explanations — tax, diversifying, a house — so it says far less than it appears to. Via SEC filings.
Congress trades
No disclosed congressional trades in MBAI.
Self-reported filings, amounts as brackets. Via Senate/House disclosures.